RATIONALE: Progesterone hypersensitivity (PH) manifests as dermatologic or other allergic symptoms during the luteal phase of the menstrual cycle. Confirming progesterone-specific IgE (sIgE) by skin testing can be unreliable. Therefore, development of a serum sIgE assay for confirming a diagnosis of PH would be useful for making appropriate treatment decisions. METHODS: Serum was obtained from patients (N581) with suspected PH. Commercially obtained progesterone-carrier protein conjugate was characterized by mass spectrometry and used to develop an IgE-specific ELISA. Sera (n53) from women with classical PH symptoms and healthy non-atopic females (N54) were used as positive and negative controls, respectively. Any value exceeding the OD cut-off (average negative control value + 3x the standard deviation) was considered positive. A subset of sera (N516) was used for ELISA-inhibition and in a mediator release assay to evaluate the specificity and functional relevance of progesterone sIgE. RESULTS: Mass-spectrometry demonstrated a shift of z 4400 Da for the progesterone-conjugate compared to the unconjugated carrier-protein indicating attachment of multiple progesterone molecules to the carrier protein. The results of the direct progesterone sIgE ELISA ranged from highly positive (> 2x OD cut-off), mildly positive (>1x to < 2x OD cut-off) and negative (< _1x OD cut-off) in 37%, 27% and 36% of sera, respectively. Using progesterone sIgE ELISA-positive sera compared to sIgE ELISAnegative or healthy control sera. ELISA inhibition and beta-hexosaminidase mediator release confirmed specificity and functional relevance of progesterone-sIgE, respectively. CONCLUSIONS: This ELISA is reliable for detecting increased functionally relevant progesterone sIgE in patients with suspected PH.
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High Frequency of S2377X mutation in Filaggrin 2 gene among Brazilian Patients with Atopic Dermatitis: no significant association with severity or persistence of disease Wagner Narciso de Campos; School of Medicine of Ribeirão PretoUniversity of São Paulo, Ribeirão Preto, Brazil. RATIONALE: We have previously shown that Brazilian patients with moderate-to-severe Atopic Dermatitis (AD) who remained symptomatic despite anti-inflammatory and immunosuppressant therapy presented filaggrin (FLG) expression comparable to control individuals on skin biopsies (JACI 2016; 137,AB144) . FLG-2 S2377X mutation has been associated with more persistent AD in children of African ancestry. We have investigated FLG-2 mutations in AD patients and correlated results with clinical parameters. METHODS: FLG-2 region of exon 3 encompassing the mutations S2377X and X2392S was amplified by PCR and sequenced by Sanger technique in 52 adult patients with AD. Total IgE and IgE to Der p1 and Der p2 were determined by ImmunoCAP and ImmunoCAP-ISAC. Vitamin D was measured by chemiluminescence. RESULTS: S2377X mutation was identified in 24/52 (46%) patients (4 homozygous) and X2392S in one patient (heterozygous) who also presented S2377X mutation. There were no significant differences in: age at onset of symptoms (median 5 and 6.5 years); duration of disease (mean 22.5 and 19.1 years); SCORAD (mean 32.9 and 39.6); total IgE (median 1,439 and 3,635IU/mL); IgE to Der p1 (median 22.3 and 32.3ISU) and Der p2 (median 27.5 and 36.8ISU); vitamin D (mean 24.9 and 25.2ng/ mL) and peripheral blood eosinophils (median 450 and 400/mm3), in patients bearing FLG-2 S2377X mutation, as compared to those without the mutation, respectively. CONCLUSIONS: In Brazilian patients with moderate to severe AD, the presence of S2377X FLG-2 mutation was not associated with persistence or severity of disease. Our results suggest that other factors including type-2 driven inflammation may play a more important role in pathogenesis.
Prostaglandin Levels in the Tears of Patients with Mucous Membrane Pemphigoid
Fadi Alkhatib, DO, and Johnny Nguyn, DO; Larkin Community Hospital, South Miami, FL. RATIONALE: Mucous Membrane Pemphigoid is a rare and debilitating disease that affects bodily mucous membranes, especially those of the eyes and oropharynx. It results in ocular surface disease leading to scarring, lid abnormalities and vision loss. Hypertrichosis associated with increased local prostaglandin levels due to topical medication or other types of ocular inflammation has been well documented. We hypothesize that mucous membrane pemphigoid also increases local prostaglandin levels and this increased concentration of prostaglandin contributes to an enhanced lash growth rate. METHODS: Our pilot study examined 4 eyes with biopsy confirmed MMP and compared them to 4 normal eyes from control patients. Tear samples were collected at the slit lamp with microcapillary pipettes and processed using an ELISA kit for PGE2. Lashes both trichiatic and normal were epilated from a predetermined location; four weeks later lashes from the same location were re-epilated and measured using Castro-Viejo calipers. RESULTS: We found statistically significant differences in both baseline prostaglandin levels (227.89 +/-32.09 pg/ml vs. 472.23 +/-51.86 pg/ml; [p<0.05]) and lash length (4.08 mm +/-0.54 vs. 5.72 mm +/-0.19; [p<0.05]) between control and study eyes measured over a 4-week period. CONCLUSIONS: This is a novel concept in regards to lash growth in response to inflammatory mediators and may help further our understanding of the complex interaction between the ocular and adnexal surface. Furthermore, treatment options such as NSAID use during the early stages of MMP may help delay the progression of trichiasis and ultimately the devastating effect it causes on the ocular surface.
